To determine whether replacement of protocol-driven repeat prostate biopsy (PB) with multiparametric magnetic resonance imaging (mpMRI) AE repeat targeted prostate biopsy (TB) when evaluating men on active surveillance (AS) for low-volume, lowto intermediate-risk prostate cancer (PCa) altered the likelihood of or time to treatment, or reduced the number of repeat biopsies required to trigger treatment.
Introduction
Active surveillance (AS) is an observational follow-up strategy, the aim of which is to avoid potentially unnecessary immediate radical therapy in selected patients with newly diagnosed lowvolume, low-to intermediate-risk, localized prostate cancer (PCa) [1] [2] [3] [4] [5] . This management involves the close monitoring of patients in order to avoid unnecessary 'over-treatment' of indolent tumours (as treatment interventions can be associated with significant short-and long-term complications), without compromising disease-specific mortality [6] [7] [8] . If disease progression occurs during AS, or if the patient requests treatment, then at this point radical treatment with curative intent may be offered [3, 6, 8] . In the UK, as in many other Western countries, AS protocols have historically involved serial PSA testing, DRE and protocol-driven transrectal repeat prostate biopsies (PBs) at arbitrary time points [3, 9, 10] . It is recognized that the timing of PB varies between different AS protocols [11] , and that the identification of optimal timing for the PB procedure is difficult. Moreover, the necessity for repeated PB among men on AS protocols repeatedly exposes them to the morbidity and risks of this invasive procedure [12] .
An increasing number of men are living with a diagnosis of PCa, and it is likely that the number of patients selecting AS for lowvolume low-to intermediate-risk PCa will continue to increase annually [2] . As such, an increasing number of men could be subject to PB as part of AS protocols. In 2014, an update to the UK National Institute for Health and Care Excellence (NICE) PCa clinical guidelines [13, 14] recommended that multiparametric MRI (mpMRI) be incorporated into AS protocols and should drive repeat biopsies where needed. In our large tertiary referral unit, we replaced the arbitrarily timed PB with an mpMRI AE repeat targeted prostate biopsy (TB) after the publication of the 2014 NICE guidelines, with a TB being undertaken where a radiologically significant lesion was seen on mpMRI as part of AS.
The objectives of the present study were threefold: to determine whether the replacement of PB with mpMRI AE TB altered (i) the likelihood that or (ii) the rate at which men discontinued AS and received treatment, and (iii) to investigate whether this change in protocol reduced the number of repeat biopsies required to trigger treatment.
Patients and Methods
After obtaining institutional review board approval, all patients undergoing AS in the period 2010-2016 were identified from the Oxford Urology Department registry, and a retrospective chart review was conducted to identify AS protocol investigation results and details of treatment intervention. The final cohort included 461 patients on AS, 445 (97%) of whom had complete follow-up data available for analysis. The baseline characteristics of the AS cohort are summarized in Table 1. Table 2 outlines the 'pre-2014' and '2014-present' AS protocols adopted for use in our unit, with patients being seen in a dedicated nurse practitioner-or urology consultant-led dedicated AS clinic, with appropriate counselling. None of the patients in our cohorts had undergone a pre-biopsy mpMRI ahead of their initial diagnostic biopsy, as that investigation had not yet been introduced into the PCa pathway at our institution.
The results of PB and mpMRI + TB investigations for men on AS are reviewed and discussed in our weekly Uro-Oncology Multi-Disciplinary Team meetings for quality assurance purposes, and treatment recommendations (which may include the option of remaining on AS if appropriate) are then discussed with the patient in dedicated AS clinics.
Multiparametric MRI
Images were acquired using either a 1.5-or 3-Tesla scanner (GE Medical Systems, Milwaukee, WI, USA). T2 images were acquired in three planes, along with axial T1, high b-value diffusion weighted images, and dynamic contrast-enhanced images, which resulted in a full mpMRI investigation.
Prostate Biopsy
Before the introduction of mpMRI as part of AS in our institution in 2014, PB was performed with TRUS guidance as a 10-or 12-core biopsy under local anaesthetic. Since the introduction of AS mpMRI in our institution in 2014, cognitively guided TRUS-guided TB post-mpMRI has been performed under local anaesthetic, including systematic repeat sampling of the prostate gland with a 10-or 12-core biopsy in addition to targeted samples. At the time of data collection for this cohort, our practice was to include the cognitively guided TRUS-guided TB cores in the same formalin pot as the systematic cores taken from that side of the prostate, whilst the systematic cores from the opposite side of the prostate were sent in a second formalin pot.
Outcomes and Statistical Analyses
The main objective of the present study was to look at the time to treatment (TTT; i.e. discontinuing AS) and compare it among different groups of patients, identified on the basis of whether they underwent mpMRI and/or biopsies ('no mpMRI and no PB', 'PB alone', 'mpMRI AE TB' and 'PB and mpMRI AE TB') or according to the type of biopsy they received ('no biopsy', 'PB alone', 'TB alone' and 'both PB and TB'). The endpoint of TTT was chosen as it is recognized that the drivers for treatment intervention in patients on AS are variable, including 'biological reclassification' of PCa (in the form of either an increase in Gleason grade group, number of positive prostate biopsy cores, or increase in maximum cancer core length), PSA progression, patient choice or increasing anxiety, or on the basis of new mpMRI changes alone. Analysis of treatmentfree survival was carried out using Kaplan-Meier plots and log-rank tests with a 5% significance level. Potential statistically significant differences in continuous patient characteristics at baseline were investigated using the Kruskal-Wallis test.
The median number of repeat biopsy procedures per patient needed to trigger treatment intervention in patients who discontinued AS having had a repeat biopsy was also reported for each group.
Results
The median (interquartile range [IQR]) length of follow-up of patients on AS in the present cohort was 2.4 (1.2-3.7) years. Of these patients, 421 (98%) had low-volume Gleason grade group ≤2 disease, with the remaining 10 patients (2%) having low-volume Gleason grade group ≥3 disease but commencing AS because of a high level of competing comorbidities. During the study period, 132 patients (30%) discontinued AS and underwent treatment intervention. The median (IQR) TTT was 1.55 (0.71-2.4) years. The treatment-free survival time for the overall cohort is shown in Fig. 1A . Of the 132 Log-rank test p=0.7471
Log-rank test p=0.0033 Table 3 ). The commonest trigger for treatment intervention was disease upgrade on repeat biopsy (71/132 patients, 48%). Most commonly, that upgrade of PCa occurred on TB performed after AS mpMRI (n = 43, 29%), while other triggers for treatment included the result of PB alone (n = 28, 19%), PSA progression (n = 36, 24%), the result of AS mpMRI alone (n = 15, 10%), or patient choice (n = 26, 18%; Table 3 ).
No significant difference was observed in the rate at which men in the PB alone group (20/41, 49%, median TTT = 1.9 years) or the mpMRI AE TB group (55/225, 24%, median TTT = 1.33 years) discontinued AS and received treatment intervention (P = 0.747; Fig. 1B ). Considering all four groups (no mpMRI and no PB; PB alone; mpMRI AE TB; PB and mpMRI AE TB) in the AS cohort, men who did not undergo either mpMRI or PB/TB discontinued AS and received treatment earlier than the other groups (P = 0.005; no mpMRI and no PB group: 29/103, 28%, median TTT = 0.51 years; PB alone group: 20/41, 49%, median TTT = 1.9 years; mpMRI AE TB group: 55/225, 24%, median TTT = 1.33 years; PB and mpMRI AE TB group: 28/76, 37%, median TTT = 3.05 years; P = 0.005 [ Fig. S1A] ) .
Considering only those patients who underwent a repeat biopsy as part of AS, a greater proportion of those who received mpMRI + TB (29/66, 44%, median TTT = 1.9 years) discontinued AS compared with those who underwent PB alone (32/87, 37%, median TTT = 1.9 years; P = 0.003 [ Fig. 1C] ). Considering the entire AS cohort (i.e. including those individuals who underwent any repeat biopsy, and those who were not re-biopsied), a greater proportion of individuals who received both a PB and a TB after mpMRI (16/30, 53%, median TTT = 3.8 years) discontinued AS than in other groups (TB following mpMRI group: 29/66, 44%, median TTT = 1.9 years; no PB and no TB group: 55/262, 21%, median TTT = 0.7 years; PB alone group: 32/87, 37%, median TTT = 1.9 years; P = 0.018 [ Fig. S1B] ). Within the entire AS cohort, patients receiving either a PB or mpMRI + TB were younger and fitter with a lower Charlson comorbidity score (P < 0.01 for each; Table 4 ). No statistically significant difference was observed in the PSA level of patients receiving mpMRI + TB, PB alone, mpMRI + TB and PB, or no biopsy at all. There were differences of borderline significance in prostate volume (P = 0.054) and PSA density (P = 0.095) among biopsy groups, with patients receiving both mpMRI + TB and PB having a trend towards a smaller prostate volume and higher PSA density compared with the other three groups, although the number of patients in this particular group was small (n = 30).
Finally, we investigated the median number of repeat biopsy procedures needed to trigger treatment intervention in patients discontinuing AS having had a repeat biopsy. We observed that on average a single set of repeat prostate biopsies was needed to trigger treatment intervention, regardless of whether this was a PB or a TB after previous mpMRI (Table 5 ).
Discussion
In this observational cohort study we investigated the effects of introducing mpMRI AE TB as a replacement for PB within our institutional AS protocol for low-volume, low-to intermediate-risk localized PCa. mpMRI of the prostate is regarded as having high-performance characteristics with regard to the localization of clinically significant PCa within the gland [15, 16] , and can identify tumours in areas of the prostate that are not sampled adequately by systematic biopsies alone [17] . mpMRI + TB has been shown to improve the detection of high-grade PCa compared with systematic biopsy alone [15, 16, 18] , therefore, the incorporation of mpMRI into AS protocols could be advantageous. The present analysis suggests that mpMRI can provide a useful function as an adjunct to regular clinical examinations and serum PSA assays as a basis for monitoring low-volume, lowto intermediate-risk PCa, and could potentially replace the undertaking of a PB, provided TBs are performed if the mpMRI identifies a new lesion. Repeat PB procedures are invasive, with a 1-3% risk of urosepsis via the transrectal route despite antibiotic prophylaxis [19, 20] . Moreover, transrectal biopsies without prior mpMRI (which aids location of lesions such as those in the anterior prostate) [21] [22] [23] [24] [25] [26] [27] [28] [29] have the potential to inadequately sample the gland, and in keeping with this, between a third and a half of men have had disease upgrading at subsequent radical prostatectomy [30, 31] . It is therefore possible that replacing PB with mpMRI AE TB where needed in the case of radiologically significant lesions could benefit men on AS programmes, as the introduction of mpMRI can help to minimize the invasive nature of monitoring for disease progression. Prostate mpMRI also has the potential to overcome some of the limitations of PB through localization of significant tumours in the prostate, and, in conjunction with TB, may improve sampling and detection of clinically significant PCa, thereby aiding the process of identifying those men on AS who require treatment. We observed that replacing the PB with mpMRI in our AS protocol led to no significant change in the time to re-classification of disease leading to treatment, suggesting that the altered AS strategy is not detrimental in terms of triggering intervention.
The invasiveness of a PB, and the high rates of associated morbidity, make this procedure a highly unpopular aspect of many AS protocols [32, 33] . Our most important observation is that patients who underwent TB after mpMRI as part of AS were significantly more likely to be re-classified and undergo treatment than those who underwent PB alone. This suggests that the mpMRI + TB approach may be more efficient than PB alone at upgrading PCa and indicating the need for treatment intervention through disease reclassification. A limitation of the present study, however, is that the cohort had not received an initial pre-biopsy mpMRI ahead of the original PCa diagnosis, with this initial investigation only being introduced more recently (in mid-2016) into the PCa pathway at our institution. It is likely that some patients receiving their first mpMRI as part of AS in our cohort will have been found to have clinically significant PCa after the AS mpMRI + TB that would have been undersampled at the original diagnostic transrectal biopsy performed before commencing AS. It may be the case that most of the individuals on an AS protocol have their PCa reclassified after that initial mpMRI, especially if there had not been a pre-biopsy mpMRI ahead of the original diagnostic prostate biopsy. Fewer patients may be reclassified after a second or third mpMRI as part of AS; however, longer follow-up of our cohort is ongoing, and this analysis will be conducted in due course, in order to investigate this possibility.
Our observation that one-third of men discontinued AS and progressed to receive treatment intervention is likely to be partly attributable to true clinical progression, and partly attributable to under-sampling of clinically significant PCa at the initiation of AS that was subsequently found after performing the mpMRI. It is likely to be the case that a PB as part of historical AS protocols, which predominantly sample the peripheral zone of the prostate gland, may continue to under-sample clinically significant PCa without the introduction of mpMRI into AS protocols, compared with mpMRI AE TB. The results of the present study are based on our practice of cognitive TB at the time of clinical management of this AS cohort. Cognitive fusion is widely practised in Europe and the USA, where uptake of costly software fusion platforms and capacity for in-gantry biopsy remains patchy for economic reasons. Furthermore, because of a paucity of studies directly comparing two or more biopsy methodologies, and variations in study populations, it is difficult currently to reach conclusions regarding which of the different available biopsy methods is optimal [34] .
Of those patients who discontinued AS, the greatest indicator of a need for treatment intervention was disease upgrade at repeat biopsy, with this occurring in approximately one-third of patients discontinuing AS. This figure is comparable with published upgrade rates of 24-36% among contemporary AS cohorts [8, 9, 35, 36] . mpMRI has been reported to be useful in evaluating patients who are potentially eligible for entry into AS, with 10-30% of patients being found to have disease that warrants active treatment after undergoing mpMRI at the time of potential entry into AS programmes [36, 37] . The undertaking of a TB after detection of a radiological lesion on an AS mpMRI allows the specific sampling of those lesions; however, in addition to this, systematic biopsies are simultaneously taken, and further research is needed to evaluate the relative contribution of the systematic and targeted biopsies in reclassifying the approximately 30% of men with disease upgrade on AS. It is a recognized limitation of the present study that we were unable to describe the relative contribution of the TB cores, versus the systematic cores, to any disease upgrade or reclassification that may result in treatment intervention. In addition, further research is warranted to better understand the nature of clinically significant PCa that is missed on mpMRI, and why some men have PCa progression that is not visible on mpMRI. While mpMRI may be able to replace PB in terms of monitoring patients on AS [38, 39] , it is necessary to define more clearly what constitutes PCa progression on mpMRI, and to identify circumstances where repeat PB can perhaps safely be avoided altogether, and how best to incorporate the timing of mpMRI into contemporary AS protocols. There is evidence to suggest that use of an mpMRI-based AS nomogram to determine whether repeat PB is indicated can spare the need for repeat PB in 47-68% of the AS cohort based on mpMRI findings [40] . Men with stable mpMRI findings have a high negative predictive value for Gleason upgrading on subsequent PB, suggesting that men may potentially be monitored by serial mpMRI examinations, with repeat PB being reserved for those with significant changes on imaging. Further long-term outcome data are needed to establish the role of serial mpMRI monitoring, instead of serial PB, for detecting disease progression in men on AS.
In conclusion, our results show that replacing PB with mpMRI-driven TB increases the chance of re-classification of patients on a contemporary AS protocol. This implies an improvement in the ability of AS evaluations to more quickly identify and treat men harbouring clinically significant disease. Hence, the use of mpMRI as part of AS to drive a TB where necessary, with the aim of identifying true disease progression or original under-sampling, represents a significant advance in the safety of AS protocols.
